Intellia Therapeutics (XTER:38I) Cyclically Adjusted PS Ratio: (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:38I Intellia Therapeutics Inc XTER:38I
53 GF Score
Price €11.10
GF Value €11.34
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Intellia Therapeutics Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Intellia Therapeutics  (XTER:38I) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Intellia Therapeutics Cyclically Adjusted PS Ratio Related Terms


Intellia Therapeutics Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Intellia Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intellia Therapeutics Cyclically Adjusted PS Ratio Chart

Intellia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 15.15 11.16

Intellia Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.78 21.56 11.16 15.51 20.86

XTER:38I vs : Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Intellia Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intellia Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's Cyclically Adjusted PS Ratio falls into.


XTER:38I
53GF Score
Intellia Therapeutics Inc XTER:38I
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intellia Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Intellia Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Intellia Therapeutics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.057/333.9520*333.9520
=0.057

Current CPI (Jun. 2026) = 333.9520.

Intellia Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.142 241.428 0.196
201612 0.156 241.432 0.216
201703 0.179 243.801 0.245
201706 0.169 244.955 0.230
201709 0.208 246.819 0.281
201712 0.170 246.524 0.230
201803 0.178 249.554 0.238
201806 0.179 251.989 0.237
201809 0.172 252.439 0.228
201812 0.178 251.233 0.237
201903 0.231 254.202 0.303
201906 0.243 256.143 0.317
201909 0.219 256.759 0.285
201912 0.222 256.974 0.289
202003 0.256 258.115 0.331
202006 0.305 257.797 0.395
202009 0.378 260.280 0.485
202012 0.108 260.474 0.138
202103 0.096 264.877 0.121
202106 0.096 271.696 0.118
202109 0.098 274.310 0.119
202112 0.173 278.802 0.207
202203 0.151 287.504 0.175
202206 0.185 296.311 0.209
202209 0.174 296.808 0.196
202212 0.156 296.797 0.176
202303 0.144 301.836 0.159
202306 0.154 305.109 0.169
202309 0.135 307.789 0.146
202312 -0.021 306.746 -0.023
202403 0.303 312.332 0.324
202406 0.072 314.175 0.077
202409 0.090 315.301 0.095
202412 0.126 315.605 0.133
202503 0.161 319.799 0.168
202506 0.137 322.561 0.142
202509 0.125 324.800 0.129
202512 0.198 324.054 0.204
202603 0.127 330.213 0.128
202606 0.057 333.952 0.057

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Intellia Therapeutics (XTER:38I) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of €11.10 is trading 2.1% below its estimated GF Value™ of €11.34. GuruFocus considers Intellia Therapeutics to be Fairly Valued.

Key valuation signals for XTER:38I:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €11.34 vs. price of €11.10 (2.1% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the XTER:38I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Intellia Therapeutics Business Description

Comparable Companies
Other Exchanges NTLA:USA0JBU:UK
Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
53GF Score

Get the complete analysis for XTER:38I

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.10
Price
€11.34
GF Value